Stock CBIO CATALYST BIOSCIENCES
Add to a list
To use this feature you must be a member
Log inSign up

News Catalyst Biosciences

Equities

CBIO

US14888D2080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
16.48 USD -1.96% Intraday chart for Catalyst Biosciences -2.25% +114.88%
2023 Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index CI
2023 Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Catalyst Biosciences : GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts - Form 8-K
PU
Catalyst Biosciences : GNI Group Updates Full Year 2023 Consolidated Earnings Forecast - Form 8-K
PU
Catalyst Biosciences : Change in Certifying Accountants - Form 8-K
PU
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
AQ
Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index
CI
Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.
CI
Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.
CI
Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.
CI
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc
CI
North American Morning Briefing : China Trouble Hits Sentiment
DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders
MT
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO
BU
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
North American Morning Briefing : Hopes Build for -3-
DJ
CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
CATALYST BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CBIO Stock
  4. News Catalyst Biosciences